Navigation Links
Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014
Date:7/31/2014

SAN FRANCISCO, July 31, 2014 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the second quarter ended June 30, 2014.

Cash and investments in marketable securities at June 30, 2014 were $301.4 million as compared to $309.1 million at March 31, 2014."The second half of 2014 will be an exciting time for Nektar as we look forward to significant milestones for a number of our late-stage clinical programs," said Howard W. Robin, President and Chief Executive Officer of Nektar. "The first of these is the potential US and EU approvals of Movantik™ with our partner AstraZeneca. If approved, Movantik would be the first oral targeted therapy approved for opioid induced constipation, a debilitating condition that occurs in up to 80%* of the 69 million chronic pain patients worldwide. Our partner Baxter has completed dosing in their Phase 3 study for BAX 855, a longer-acting PEGylated Factor VIII therapy to treat hemophilia A and plans to file the BLA in the U.S. by the end of this year. In our proprietary pipeline, we are on track for topline results from the Phase 3 breast cancer study for NKTR-102 in Q1 2015."

Revenue in the second quarter of 2014 was $28.5 million as compared to $33.9 million in the second quarter of 2013. Year-to-date revenue for 2014 was $48.3 million as compared to $56.9 million in the first half of 2013.  The decrease in revenue in the second quarter and first half of 2014 as compared to the same periods in 2013 is primarily due to decreased manufacturing activity.  Revenue included non-cash royalty revenue, related to our 2012 royalty monetization, of $4.8 million and $10.6 million in the second quarter and first half of 2014, respectively, and $3.8 million and $8.2 million in the second quarter and first half of 2013, respectively. This non-cash royalty revenue is offset by non-cash interest exp
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Nektar to Announce Financial Results for the Second Quarter 2014 on Thursday, July 31, 2014, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
3. Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
4. Nektar to Announce Financial Results for the Third Quarter of 2013 on Thursday, November 7, 2013, After Close of U.S.-Based Financial Markets
5. Nektar Reports that Partner AstraZeneca Announced European Medicines Agency Acceptance of Marketing Authorisation Application for Naloxegol
6. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2013
7. Nektar to Announce Financial Results for the Second Quarter of 2013 on Thursday, August 8, 2013, After Close of U.S.-Based Financial Markets
8. Nektar Completes Enrollment in Phase 3 BEACON Study of Etirinotecan Pegol in Women With Metastatic Breast Cancer
9. Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
10. Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting
11. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... - Medicure Inc. (the "Company") (TSXV:MPH, OTCQB:MCUJF) announces today ... of an aggregate of 236,070 options to certain directors, ... Company pursuant to the Company,s Stock Option Plan. Of ... tenth anniversary of the date of grant, 5,000 are ... date of grant and 50,000 are set to expire ...
(Date:3/27/2015)... Telbec/ - Russell Williams , President of ... the 2015-2016 Quebec Budget, noting the fiscal discipline and ... industry. However, the association is concerned about the decline ... government,s intent to strive for a balanced budget this ... Quebec,s economic development is encouraging," said ...
(Date:3/27/2015)... , March 27, 2015 Biopharmaceutical ... The biopharmaceutical industry comes out on top as the ... a new report  from ndp│analytics. According to the  ... development (R&D) investment over the last decade, accounting for ... A Short Video on Medicare ...
Breaking Medicine Technology:Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 2Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 3Week in Review: The Latest from PhRMA 2
(Date:3/28/2015)... New York, NY (PRWEB) March 28, 2015 ... 2015 highlighted a problem which could prove critical to ... Why system testing, a critical aspect of data security, ... payment card industry data security report, every major category ... vulnerability scanning and penetration testing. “With all the craziness ...
(Date:3/28/2015)... Delaying rotator cuff surgery on patients ... research presented today at the American Orthopaedic Society for ... study compared results for 170 patients who received rotator ... joint capsule release procedure to relieve stiffness at the ... author from St. George Hospital in Sydney, Australia. “Both ...
(Date:3/28/2015)... Omaha, NE (PRWEB) March 28, 2015 ... leader in healthcare staffing, including physical therapy jobs, ... exhibitor at the Ohio Physical Therapy Association Annual ... the Renaissance Columbus Downtown Hotel in Columbus, OH. ... programming, networking opportunities, and exhibits with products and ...
(Date:3/28/2015)... 2015 Purity Products®, a leading ... the release of their revolutionary new weight loss ... randomized, double-blind, placebo-controlled clinical studies to be effective ... size. MuffinStop™ is a combination of two traditionally ... fused together to create one of the most ...
(Date:3/27/2015)... In her mid-forties and with a lifelong ... Monica K. arrived at JET Uniform & Supply ... and scared. The owners and staff at JET, which had ... to offer jobs to challenged residents like Monica, were patient. ... to begin with the end in mind,” says Stephen Milaney, ...
Breaking Medicine News(10 mins):Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 2Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 3Health News:Businesses Dealing With PCI Falling Short On Regular Vulnerability Scans and Pen Testing 4Health News:No Need to Delay Rotator Cuff Surgery, Study Shows 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the Ohio Physical Therapy Association Annual Conference 2Health News:Purity Products Releases Revolutionary New Weight Loss Product, MuffinStop™ 2Health News:Red Deer Uniforms Shop Celebrates 3rd Year Sewing Hope for the Challenged 2Health News:Red Deer Uniforms Shop Celebrates 3rd Year Sewing Hope for the Challenged 3
... creating a new and unusual "app" for the smart phone: tracking ... social and preventive medicine, has received a grant to assess a ... in this case, the City of Buffalo. The study ... of Health (NIH). A city,s air pollution varies from ...
... Mass. Nearly one-half of U.S. adults who use ... include health-focused networks, not much is known about their ... studies of social networking websites targeting patients, researchers in ... evaluation of ten diabetes websites. Their audit ...
... release is available in Spanish . , ... Higher Institute for Scientific Research (CSIC) have made significant ... in the development of cosmetic and drug products, and ... Phospholipid vesicles (liposomes) are colloidal systems that arise ...
... and head trauma is due to damage caused the overproduction ... damage has been impossible, until now, as many drugs don,t ... don,t work as intended. But a method originally devised at ... a way to avert such glutamate-induced harm. Prof. ...
... , TUESDAY, Feb. 8 (HealthDay News) -- Medication errors ... occur if residents are given pills or capsules dispensed from ... A monitored dosage system is a tray or cassette ... day or a given time. They,re designed to simplify drug ...
... will get them into consumers, hands quicker, but may not ... has found. A mathematical model created by Andrew Ching ... of getting there first and commanding the best profits are ... an associate professor of marketing at the University of Toronto,s ...
Cached Medicine News:Health News:New study to use smart phones to track air pollution exposure 2Health News:Quality varies in social networking websites for diabetics 2Health News:Quality varies in social networking websites for diabetics 3Health News:New data obtained on liposomes employed in drug encapsulation and gene therapies 2Health News:Hope for stroke victims 2Health News:Daily Pill Dispensers an Asset in Homes for Elderly: Study 2
... used for endophotocoagulation indications, include tapered, ... and illuminating models. The full line ... uncompromised laser treatment of intravitreal pathologies. ... that are flexible and convenient to ...
Anterior chamber protein meter. Can be used for both slit and flare measurement....
... for flexible continuous monitoring, the M3 and ... pediatric and neonatal patient care. M Series ... that includes a basic set of non-invasive ... temperature. Optional Multi-Measurement Server extensions offer Mainstream ...
Compact networked patient monitors for flexible care....
Medicine Products: